State of New Jersey Common Pension Fund D Sells 3,039 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

State of New Jersey Common Pension Fund D reduced its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 5.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,865 shares of the company’s stock after selling 3,039 shares during the quarter. State of New Jersey Common Pension Fund D owned approximately 0.06% of CRISPR Therapeutics worth $3,059,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. CWM LLC boosted its holdings in shares of CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after buying an additional 260 shares during the last quarter. Tradewinds Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 545.5% in the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after buying an additional 600 shares during the last quarter. Blue Trust Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at approximately $32,000. Headlands Technologies LLC acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $34,000. Finally, Bourgeon Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after buying an additional 500 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $53.91 on Friday. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10. The stock’s fifty day moving average is $70.57 and its 200 day moving average is $63.95.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. The firm’s revenue was up 3253.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.41) EPS. On average, analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 19,582 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Raju Prasad sold 3,524 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.69, for a total value of $256,159.56. Following the transaction, the chief financial officer now directly owns 6,476 shares in the company, valued at $470,740.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 133,992 shares of company stock valued at $9,157,835. 4.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on CRSP shares. Citigroup increased their price objective on CRISPR Therapeutics from $88.00 to $89.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Morgan Stanley raised their price target on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a report on Monday, February 26th. TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Royal Bank of Canada raised their price target on CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a report on Thursday, February 22nd. Finally, Wells Fargo & Company raised their price target on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, February 22nd. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $76.29.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.